LOC646862 Inhibitors
LOC646862 inhibitors are a class of compounds that act on various points of the TGF-β signaling pathway, which is known to orchestrate a multitude of cellular processes including cell growth, differentiation, and apoptosis. These inhibitors share a common mechanism of action: they interrupt the phosphorylation of Smad proteins, which are essential for the propagation of signals from the cell membrane to the nucleus, where they influence gene expression. For instance, SB431542, LY364947, and Galunisertib are all potent inhibitors of TGF-β type I receptors, which play a crucial role in activating Smad2 and Smad3 proteins. By blocking the kinase activity of these receptors, these compounds prevent the Smad proteins from becoming phosphorylated and subsequently translocating to the nucleus. If LOC646862 is a gene product that relies on Smad-mediated transcriptional regulation, its activity would be expected to decrease as a consequence of such inhibition.
Other compounds in this class, such as Halofuginone and LY2109761, similarly target the TGF-β/Smad signaling pathway, albeit through slightly different interactions. Halofuginone inhibits Smad3 phosphorylation, while LY2109761 serves as a dual inhibitor of TGF-β receptor I/II, thereby blocking the activation of both Smad2 and Smad3. When the phosphorylation of these Smads is inhibited, the entire cascade of downstream signaling events is disrupted.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
Small molecule inhibitor of ALK5, which is a receptor involved in TGF-β signaling. Inhibition of ALK5 by SB431542 prevents phosphorylation of Smad proteins, which could indirectly decrease LOC646862 activity if it is downstream of TGF-β signaling. | ||||||
LY 364947 | 396129-53-6 | sc-203122 sc-203122A | 5 mg 10 mg | $107.00 $156.00 | 4 | |
Inhibitor of TGF-β type I receptors, blocking ATP-binding and thus kinase activity. This action halts Smad phosphorylation, potentially causing reduced LOC646862 activity if its function is Smad-dependent. | ||||||
Halofuginone | 55837-20-2 | sc-507290 | 100 mg | $1775.00 | ||
Inhibits Smad3 phosphorylation by interfering with TGF-β signaling, which might reduce LOC646862 activity if it is a Smad3-regulated protein. | ||||||
LY2109761 | 700874-71-1 | sc-396262 sc-396262A | 1 mg 5 mg | $89.00 $275.00 | 9 | |
Selective ATP-mimetic inhibitor of TGF-β receptor I, leading to inhibition of Smad phosphorylation. This blockade could indirectly inhibit LOC646862 if it is regulated by TGF-β/Smad signaling. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $77.00 $153.00 $219.00 $663.00 $1248.00 $4382.00 $7850.00 | 8 | |
Selective inhibitor of ALK5 kinase activity, leading to inhibition of Smad2/3 phosphorylation. This could reduce LOC646862 activity if it is influenced by Smad-mediated transcription. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
Inhibitor of ALK4, ALK5, and ALK7, hindering TGF-β signaling and Smad2/3 phosphorylation, which could decrease LOC646862 function if it is Smad-responsive. | ||||||
Pirfenidone | 53179-13-8 | sc-203663 sc-203663A | 10 mg 50 mg | $102.00 $416.00 | 6 | |
Antifibrotic agent that attenuates TGF-β-driven processes, which may indirectly inhibit LOC646862 if it is implicated in fibrosis regulated by TGF-β. | ||||||
TGF-β RI Kinase Inhibitor V | 627536-09-8 | sc-203294 | 2 mg | $88.00 | 3 | |
TGF-β receptor I inhibitor that blocks Smad signaling, potentially reducing LOC646862 activity if it is part of the TGF-β signaling pathway. | ||||||
EW-7197 | 1352608-82-2 | sc-507465 | 5 mg | $345.00 | ||
TGF-β receptor I inhibitor that impedes Smad2/3 phosphorylation, potentially diminishing LOC646862 functional activity if it is TGF-β/Smad-dependent. | ||||||